Continued research and development of LLS30-based therapies is essential to devise effective strategies against drug resistance, addressing the specific mechanisms driving resistance in high Gal-1/AR-expressing prostate cancer, and providing a targeted, personalized approach to therapy. This evidence concerns the gene LGALS1 and Familial prostate cancer.